文拉法辛,临床注释,变异和临床注释数据

id	等位基因	注释文本
44	*81	The CYP2D681 allele has been assigned as a no function allele by CPIC. Patients carrying the 81 allele in combination with a decreased, normal or no function allele may may be more likely to develop side effects when treated with venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.
43	*6	The CYP2D66 allele has been assigned as a no function allele by CPIC. Patients carrying the 6 allele in combination with a decreased, normal or no function allele may may be more likely to develop side effects when treated with venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.
42	*5	The CYP2D65 allele has been assigned as a no function allele by CPIC. Patients carrying the 5 allele in combination with a decreased, normal or no function allele may may be more likely to develop side effects when treated with venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.
41	*4	The CYP2D64 allele has been assigned as a no function allele by CPIC. Patients carrying the 4 allele in combination with a decreased, normal or no function allele may may be more likely to develop side effects when treated with venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.
40	*3	The CYP2D63 allele has been assigned as a no function allele by CPIC. Patients carrying the 3 allele in combination with a decreased, normal or no function allele may may be more likely to develop side effects when treated with venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.
39	*1	The CYP2D61 allele is assigned as a normal function allele by CPIC. Patients carrying the 1 allele in combination with alleles that result in a normal metabolizer phenotype may be less likely to develop side effects when treated with venlafaxine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.

等位基因

注释文本

The CYP2D6*81 allele has been assigned as a no function allele by CPIC. Patients carrying the *81 allele in combination with a decreased, normal or no function allele may may be more likely to develop side effects when treated with venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.

The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may may be more likely to develop side effects when treated with venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.

The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may may be more likely to develop side effects when treated with venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.

The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may may be more likely to develop side effects when treated with venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.

The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may may be more likely to develop side effects when treated with venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.

The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may be less likely to develop side effects when treated with venlafaxine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.

id	证据的ID	总结
14655	982015073	CYP2D6 5/4 + 6/6 + 6/4 are associated with increased risk of side effects when treated with venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 1/1.
14654	1184467243	CYP2D6 3 + 4 + 5 + 6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.
14653	1450934262	CYP2D6 1/4 is associated with increased cardiotoxicity, Edema, Nausea and Vomiting when treated with venlafaxine in men with Alcohol-Related Disorders.
14652	1184169374	CYP2D6 1/1 + 1/10 + 1/17 + 1/3 + 1/4 + 1/41 + 1/5 is not associated with side effects when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 10/10 + 10/41 + 3/4 + 3/41 + 4/10 + 4/4.
14651	1183619024	CYP2D6 4/4 is associated with side effects when treated with venlafaxine.
14650	982029483	CYP2D6 4/4 is associated with increased risk of side effects when treated with venlafaxine in people with Depressive Disorder, Major.
14649	982015063	CYP2D6 4/4 is associated with tachycardia and agitation when treated with venlafaxine.
14648	982029474	Genotypes CT + TT are not associated with increased risk of side effects when treated with venlafaxine in people with Depressive Disorder, Major as compared to genotype CC.
14647	1043858956	Genotype AG is associated with agitation and dysphoria when treated with venlafaxine in patient with depression.
14646	1184169551	CYP2D6 normal metabolizers is associated with increased risk of side effects when treated with venlafaxine in people with Obsessive-Compulsive Disorder.
14645	PA166104968	Annotation of DPWG Guideline for venlafaxine and CYP2D6

证据的ID

总结

14655

982015073

CYP2D6 *5/*4 + *6/*6 + *6/*4 are associated with increased risk of side effects when treated with venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.

14654

1184467243

CYP2D6 *3 + *4 + *5 + *6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.

14653

1450934262

CYP2D6 *1/*4 is associated with increased cardiotoxicity, Edema, Nausea and Vomiting when treated with venlafaxine in men with Alcohol-Related Disorders.

14652

1184169374

CYP2D6 *1/*1 + *1/*10 + *1/*17 + *1/*3 + *1/*4 + *1/*41 + *1/*5 is not associated with side effects when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 *10/*10 + *10/*41 + *3/*4 + *3/*41 + *4/*10 + *4/*4.

14651

1183619024

CYP2D6 *4/*4 is associated with side effects when treated with venlafaxine.

14650

982029483

CYP2D6 *4/*4 is associated with increased risk of side effects when treated with venlafaxine in people with Depressive Disorder, Major.

14649

982015063

CYP2D6 *4/*4 is associated with tachycardia and agitation when treated with venlafaxine.

14648

982029474

Genotypes CT + TT are not associated with increased risk of side effects when treated with venlafaxine in people with Depressive Disorder, Major as compared to genotype CC.

14647

1043858956

Genotype AG is associated with agitation and dysphoria when treated with venlafaxine in patient with depression.

14646

1184169551

CYP2D6 normal metabolizers is associated with increased risk of side effects when treated with venlafaxine in people with Obsessive-Compulsive Disorder.

14645

PA166104968

Annotation of DPWG Guideline for venlafaxine and CYP2D6

id	类型	评论
272	Create	Created
97	Note	Checked
96	Update	Added DPWG guideline and PMIDs 23545896 and 31799914 to evidence. Rewrote phenotype descriptions to fit LOE 1A template. Needs independent curator check before approval.
95	Update	CA score added as part of scoring system release. LOE may have automatically changed based on new score but may be subject to further changes upon curator review.

类型

Added DPWG guideline and PMIDs 23545896 and 31799914 to evidence. Rewrote phenotype descriptions to fit LOE 1A template. Needs independent curator check before approval.

Update

CA score added as part of scoring system release. LOE may have automatically changed based on new score but may be subject to further changes upon curator review.